- Home
- TROO vs AGEN Comparison
TROO vs AGEN Comparison
Compare TROO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- AGEN
- Stock Information
- Founded
- TROO 2005
- AGEN 1994
- Country
- TROO Hong Kong
- AGEN United States
- Employees
- TROO N/A
- AGEN N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TROO Technology
- AGEN Health Care
- Exchange
- TROO Nasdaq
- AGEN Nasdaq
- Market Cap
- TROO 215.4M
- AGEN 97.7M
- IPO Year
- TROO N/A
- AGEN 2000
- Fundamental
- Price
- TROO $2.13
- AGEN $4.49
- Analyst Decision
- TROO
- AGEN Buy
- Analyst Count
- TROO 0
- AGEN 3
- Target Price
- TROO N/A
- AGEN $10.00
- AVG Volume (30 Days)
- TROO 11.0K
- AGEN 339.2K
- Earning Date
- TROO 10-29-2024
- AGEN 11-05-2024
- Dividend Yield
- TROO N/A
- AGEN N/A
- EPS Growth
- TROO N/A
- AGEN N/A
- EPS
- TROO N/A
- AGEN N/A
- Revenue
- TROO $3,569,000.00
- AGEN $159,630,000.00
- Revenue This Year
- TROO N/A
- AGEN N/A
- Revenue Next Year
- TROO N/A
- AGEN $0.04
- P/E Ratio
- TROO N/A
- AGEN N/A
- Revenue Growth
- TROO N/A
- AGEN 60.67
- 52 Week Low
- TROO $0.73
- AGEN $4.18
- 52 Week High
- TROO $4.89
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- TROO 31.08
- AGEN 40.14
- Support Level
- TROO $2.11
- AGEN $4.50
- Resistance Level
- TROO $2.29
- AGEN $4.78
- Average True Range (ATR)
- TROO 0.18
- AGEN 0.28
- MACD
- TROO -0.00
- AGEN 0.02
- Stochastic Oscillator
- TROO 4.13
- AGEN 42.47
About TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).